product hopping
Switching the market to a trivially modified, newly patented version of a drug and withdrawing the original to block generic substitution.
As defined in Robin Feldman on Drug Patents, Generics, and Drug Wars
Where it comes up · 1
Most important claims · 2 of 2Search all claims for “product hopping” →
- In the Asacol/Delzicol case the company introduced a new patented product identical to the old drug except for an ineffective capsule that did nothing, then withdrew the original Asacol from the market; because pharmacists could not substitute a generic of the now-unavailable original, and generics could not add a matching capsule without infringing the new patent, the maneuver blocked generic competition despite the change being therapeutically meaningless.Robin Feldman on Drug Patents, Generics, and Drug Wars
- Within Hatch-Waxman, companies practice evergreening and product hopping—making a minor modification to a drug's delivery, dosage, or form right as the patent expires, obtaining a new patent on the trivially changed version, and then withdrawing the old version so generics of the original cannot be substituted.Robin Feldman on Drug Patents, Generics, and Drug Wars